[{"id":"75e429d1-288b-438c-890d-57227288a551","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436254","created_at":"2021-01-18T01:32:21.652Z","updated_at":"2025-02-25T16:35:57.454Z","phase":"Phase 1","brief_title":"Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer","source_id_and_acronym":"NCT00436254","lead_sponsor":"University of Washington","biomarkers":" HER-2 • MUC16","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AST-301 • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 10/01/2001","start_date":" 10/01/2001","primary_txt":" Primary completion: 03/01/2010","primary_completion_date":" 03/01/2010","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-06"},{"id":"4354679e-5391-465c-8311-51adc5b55004","acronym":"Conerstone3","url":"https://clinicaltrials.gov/study/NCT05771584","created_at":"2023-03-16T14:02:37.509Z","updated_at":"2024-07-02T16:35:42.388Z","phase":"Phase 2","brief_title":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","source_id_and_acronym":"NCT05771584 - Conerstone3","lead_sponsor":"Aston Sci. Inc.","biomarkers":" HER-2 • CD8 • CD4","pipe":" | ","alterations":" HER-2 overexpression • HER-2 underexpression","tags":["HER-2 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AST-301 • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/04/2023","start_date":" 07/04/2023","primary_txt":" Primary completion: 10/15/2023","primary_completion_date":" 10/15/2023","study_txt":" Completion: 06/15/2026","study_completion_date":" 06/15/2026","last_update_posted":"2023-07-20"},{"id":"b6105601-6a5a-48fb-bc02-a8e3b8b010f6","acronym":"Cornerstone001","url":"https://clinicaltrials.gov/study/NCT05163223","created_at":"2021-12-20T15:53:31.143Z","updated_at":"2024-07-02T16:35:42.478Z","phase":"Phase 2","brief_title":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer","source_id_and_acronym":"NCT05163223 - Cornerstone001","lead_sponsor":"Aston Sci. Inc.","biomarkers":" HER-2 • IFNG","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • capecitabine • AST-301 • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 02/28/2022","start_date":" 02/28/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-20"},{"id":"e3f3d87c-042b-41d5-85e7-f64a91c593c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01922921","created_at":"2021-01-18T08:40:49.420Z","updated_at":"2025-02-25T14:00:14.999Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy","source_id_and_acronym":"NCT01922921","lead_sponsor":"University of Washington","biomarkers":" HER-2 • IFNG • NCAM1 • LAMP1","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • IFNG • NCAM1 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Trazimera (trastuzumab-qyyp) • AST-301"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/05/2014","start_date":" 02/05/2014","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2023-04-18"},{"id":"f3a488ea-f6b4-4372-b29a-aef4d7a8f72c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00343109","created_at":"2021-01-18T01:11:10.688Z","updated_at":"2024-07-02T16:36:50.140Z","phase":"Phase 2","brief_title":"Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer","source_id_and_acronym":"NCT00343109","lead_sponsor":"University of Washington","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • AST-301 • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2020-02-12"},{"id":"d5845265-f322-4604-92ea-75ecb5b0b4e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00363012","created_at":"2021-04-05T16:19:09.067Z","updated_at":"2024-07-02T16:37:23.794Z","phase":"","brief_title":"Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2","source_id_and_acronym":"NCT00363012","lead_sponsor":"University of Washington","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AST-301"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":" Primary completion: 03/01/2010","primary_completion_date":" 03/01/2010","study_txt":" Completion: 03/01/2010","study_completion_date":" 03/01/2010","last_update_posted":"2017-04-05"}]